Health Costs

Affordable care act

Poll: Health Care Costs, Expiring ACA Tax Credits, and the 2026 Midterms

Heading into this midterm election year, the cost of health care tops the public’s economic anxieties, and more than 4 in 10 voters say the issue will have a major impact on their vote, a new KFF Health Tracking poll finds. Two thirds of public say Congress "did the wrong thing" by not extending ACA enhanced tax credits, but Republicans largely say Congress “did the right thing.”

Affordability and Spending

Our Darwinian Approach to Health Care Costs

Our Darwinian Approach to Health Care Costs

In his latest column, President and CEO Dr. Drew Altman presents his Venn diagram of health care cost problems and shows how, in our fragmented health system, reducing one health cost problem often makes another worse. "...Reducing health care costs has become a Darwinian game; everyone wants to reduce health care costs and spending – their own, often at the expense of someone else."

KEY RESOURCES
  • Health Policy 101: Costs and Affordability

    This Health Policy 101 chapter explores trends in health care costs in the U.S. and the factors that contribute to this spending. It also examines how health care spending varies and the impact on affordability and people's overall financial vulnerability.  


  • Americans’ Challenges with Health Care Costs

    This data note reviews our recent polling data that finds that Americans struggle to afford many aspects of health care, including disproportionate shares of uninsured adults, Black and Hispanic adults and those with lower incomes.

  • National Health Spending Explorer

    This interactive Peterson-KFF Health System Tracker tool allows users to examine five decades worth of data on health expenditures by federal and local governments, private insurers, and individuals.

  • Polling on Prescription Drugs and Their Prices

    This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

131 - 140 of 1,556 Results

  • The 4 Arguments You Will Hear Against Drug Price Negotiation

    Perspective

    As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF's Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.

  • KFF Health Tracking Poll: Public Weighs in on Health Care Debate and Government Shutdown 

    Poll Finding

    This poll finds that public support remains high for extending the enhanced ACA tax credits set to expire at the end of the year. Three quarters of the public favor of extending them, though support among Republicans has dipped since September. Most Democrats want a Congressional budget deal to include an extension of the tax credits.

  • Understanding Various Measures to Assess Hospital Finances: A Cheat Sheet

    Fact Sheet

    This one-page fact sheet provides basic information for understanding measures of hospital finances. It describes profits margins and other common measures of hospitals' financial well-being, as well as considerations when evaluating reports of these measures, such as how different approaches can make these measures appear higher or lower.

  • FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program

    Issue Brief

    The Centers for Medicare & Medicaid Services (CMS) recently announced the drugs selected for the second round of negotiation for the Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and CMS's implementation of the program, with a focus on the details that apply for 2027, the second year that negotiated prices will be available under the program.